

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique identification designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

—Zimm Davis

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

Zinna Davis

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Complete if Known			
		Application Number	10/827,514		
		Filing Date	April 19, 2004		
		First Name Inventor	Bolin		
		Group Art Unit	1625		
		Examiner Name	ZNDANIS		
Sheet	2	Of	2	Attorney Docket Number	21099 US1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ³	
mgd	C1	ANSELM, ELSE, et. al., "Selective inhibition of calcium entry induced by benzylisoquinolines in rat smooth muscle", J. Pharm. Pharmacol. (1992) 44(4), 337-343		
	C2	M.A. BADET-DENISOT, et. al., Bioorg. Med. Chem. Letters, 5, 815-820 (1995)		
	C3	S.L. BEARNE, J. Biol. Chem., 271, 3052-3057 (1996)		
	C4	S.L. BEARNE, et. al., Biochem., 34, 11515-11520 (1995)		
	C5	F. BISTER-MIEL, et. al., Plantes Medicinales et Phytotherapie (1986), Tome XX, n°1, p. 3-7		
	C6	CHEN CHEN, et. al., J. Med. Chem. (2001) 44, 4001-4010		
	C7	H. CHMARA, J. Gen. Microbiol., 131, 265-271 (1985)		
	C8	MARKWARDT, FRITZ, et. al., "Influence of 6,7-dimethoxyisoquinoline derivatives on the function of thrombocytes" Acta Biologica et Medica Germanica (1969) 23(2), 295-306		
	C9	F. MASSIERE, et. al., J. Amer. Chem., Soc., 119, 5748-5749 (1997)		
	C10	S. MILEWSKI, et. al., Biochim. Biophys. Acta, 1115, 225-229 (1992)		
	C11	E. POSTAIRE, et. al., Ann. Pharmaceutiques Francaises (1985), 43, n°6, pp. 547-556		
	mgd	C12	D. WALTEROVA, et. al., Collection Czechoslov. Chem. Commun, (1980), 45, pp. 956-965	
Examiner Signature	ZNDANIS		DATE CONSIDERED	6/10/2005

²EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

³Unique citation designation number. ⁴Applicant is to place a check mark here if English language Translation or abstract is attached.

144032